Our Company
is committed to promoting health across communities
What does Amring do?
Amring sells uniquely positioned generics that bring value to customers and patients.
We spend every minute of every day figuring out how to bring historically complex prescription medications to market. Our products are generics of value to the market, not high-volume, mass-produced products.
Our Executive Team
We believe that we can deliver a better quality of life and health to the people in our communities, our families and the world.
-
Daniel CarberyPresident and CEO
-
Tatyana Kosheleva, CPA, MBAVP, Treasurer & CFO
-
Marina Volin, Esq.VP, General Counsel & Corporate Secretary
-
Thomas SammlerHead of Sales and Marketing
-
Erika Geimonen, Ph.D., M.S.VP, Business Development

Daniel Carbery
Daniel Carbery
President and CEO
Daniel Carbery is the President and General Manager of Amring. He is responsible for creating the strategic vision and operating plan for the company. Mr. Carbery is charged with driving a talented leadership team to build a new generic drug company, one that’s based on high quality products, committed employees, enduring and trusting customer relationships, global business partnerships and complete integrity.
Mr. Carbery has a successful track record building and leading franchises and serving a national consumer audience through healthcare and retail distribution channels. Before becoming a founding leader and head of Amring, Mr. Carbery was Chief Executive Officer and Board Director for Axcentria Pharmaceuticals. Previously, he held positions of increasing managerial and executive responsibility for companies including Endo Pharmaceuticals, Procter & Gamble, Nabisco and GlaxoSmithKline.
Mr. Carbery has expertise in commercial management, product development, and total supply chain activities at the national and global levels. He has proved to be a sophisticated strategist and an expert at leading operations across a range of functions, including R&D, engineering, plant operations, marketing, product development and market development. Mr. Carbery has provided strategic and business counsel to major organizations and startups.
Mr. Carbery graduated from Princeton University with a degree in Chemical Engineering and earned his MBA from Rutgers University.

Tatyana Kosheleva, CPA, MBA
Tatyana Kosheleva, CPA, MBA
VP Treasurer & CFO
Tatyana Kosheleva is Head, Finance and Corporate Treasurer for Amring Pharmaceuticals Inc. In this role, Ms. Kosheleva is responsible for supporting the company’s financial growth. She oversees forecasting and planning, accounting, liquidity management, internal controls, compliance, purchasing, and bank and audit relationship management. Ms. Kosheleva is a member of Amring’s Executive Board, and reports directly to the President of Amring.
Ms. Kosheleva has extensive international financial and operational expertise, with a career that spans more than two decades and four countries. Before joining Amring, she was Finance Director at Russian subsidiary of Ferring Pharmaceuticals. Prior to that, Ms. Kosheleva served as Chief Financial Officer at DST Global Solutions, a London-based subsidiary of DST Systems, with offices in nine countries.
Ms. Kosheleva is a licensed CPA and holds an MBA from Thunderbird School of Global Management, a part of the Arizona State University.

Marina Volin, Esq.
Marina Volin, Esq.
VP, General Counsel & Corporate Secretary
Marina joined Amring Pharmaceuticals in May 2020 as Vice President, General Counsel & Corporate Secretary. She oversees all legal matters for the company including contractual agreements, corporate governance, intellectual property, compliance matters and due diligence for business development opportunities.
With more than 20 years of experience representing pharmaceutical companies, Marina came to Amring from Kintai Therapeutics of Cambridge, MA where she served as Vice President, Head of Legal and Intellectual Property. Prior to that, she served as Intellectual Property and Corporate Attorney for Windtree Therapeutics, Inc. (formerly Discovery Labs) of Warrington, PA. Marina began her legal career with the law firm Caesar Rivise, PC of Philadelphia, PA. Prior to studying law, Marina served as Scientific Assistant at the Fox Chase Cancer Center, Philadelphia, PA.
Marina earned her Juris Doctorate degree from the Temple University School of Law in Philadelphia and Master of Science and Bachelor of Science degrees in Chemical Engineering from the Gubkin Russian University of Oil and Gas in Moscow. She is a member of the New Jersey and Pennsylvania Bar Associations.

Thomas Sammler
Thomas Sammler
Head of Sales and Marketing
As Head, Sales and Marketing, Mr. Sammler is responsible for the strategy and tactical execution of the Amring commercial product portfolio. He leads the identification and pursuit of profitable sales growth at the national, regional, and local level, across Retail, Specialty and Institutional Pharmacy. He also helps carry out growth initiatives, such as business development activities, to ensure strong, sustained P&L performance for the company.
Before joining Amring in September 2015, Mr. Sammler was Director, Sales Operations for Impax Laboratories. In that position, he managed sales operations during the company’s integration with the Tower Holding companies. Previously, Mr. Sammler held various marketing and financial positions at CorePharma, Sandoz, Endo Pharmaceuticals and DuPont/DuPont Merck. He has experience driving revenues for both generic and branded pharmaceutical products and leading a diverse range of commercial operations, from sales teams and product marketing to supply chain logistics and strategic planning.
Mr. Sammler graduated with a B.S. in Accounting from Widener University and earned his MBA in Pharmaceutical Marketing from Saint Joseph’s University.

Erika Geimonen, Ph.D., M.S.
Erika Geimonen, Ph.D., M.S.
VP, Business Development
Erika Geimonen serves as Vice President, Business Development for Amring Pharmaceuticals. She is responsible for analyzing the market landscape to identify opportunities in product licensing, partnering and acquisitions that will help Amring Pharmaceuticals reach its strategic objectives. She evaluates the company’s business development opportunities, including M&A, in-licensing, divestment, alliances and out-licensing. She also leads the due diligence team that oversees all company acquisitions.
Dr. Geimonen has more than 23 years of experience in business development and research. Before joining Amring Pharmaceuticals, she was the Chief Operating Officer and Vice President, Business Development for Dynamis Therapeutics. In that position, she was responsible for all business development activities, managing operations, and raising capital for the company. Previously, Dr. Geimonen held business development positions at XBiotech, Luitpold Pharmaceuticals and Schering-Plough. Earlier in her career Dr. Geimonen held a series of research roles.
Dr. Geimonen co-chairs the Philadelphia chapter of Licensing Executives Society. She earned her M.S. in Biology and Ph.D. in Biology and Biochemistry from Moscow State University in Russia and an M.S. in Management and Policy from the College of Business at the State University of New York at Stony Brook.
Our History
We may be new to the market, but we share the technology, maturity and capability of a nearly 70 year-old healthcare group.
1935
Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.

1950
The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.
1954
The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.
1960
Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.
2015
Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.
2015
Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..

2016
Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.
2016
Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.
2017
Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.
2017
Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.
2018
Amring enters the Medical Device with the launch of Biolon® OVD.
2018
Amring launches Arsenic Trioxide Injection – the first product from its development portfolio.
2018
Amring closes on a product acquisition deal that adds at least 3 new products to its portfolio.
2019
Amring Launches Succinylcholine Chloride Injection, a generic of Quelicin®.
2019
Amring Launches Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories.
2020
Amring acquires the global rights to LYSTEDA® (tranexamic acid).
2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program.
2021
Amring launches Isoproterenol Hydrochloride Injection, USP, a generic version of Isuprel®.
2022
Amring launches Lamotrigine Orally Disintegrating Tablets (ODT), USP, a generic of Lamictal®
2022
Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%.
1935
Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.
1954
The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.
1960
Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.
2015
Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..
2016
Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.
2017
Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.
2018
Amring launches Arsenic Trioxide Injection – the first product from its development portfolio.
2019
Amring Launches Succinylcholine Chloride Injection, a generic of Quelicin®.
2020
Amring acquires the global rights to LYSTEDA® (tranexamic acid).
2021
Amring launches Isoproterenol Hydrochloride Injection, USP, a generic version of Isuprel®.
2022
Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%.

1950
The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.
2015
Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.

2016
Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.
2017
Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.
2018
Amring enters the Medical Device with the launch of Biolon® OVD.
2018
Amring closes on a product acquisition deal that adds at least 3 new products to its portfolio.
2019
Amring Launches Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories.
2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program.
2022
Amring launches Lamotrigine Orally Disintegrating Tablets (ODT), USP, a generic of Lamictal®
Amring is a proud member of the global pharmaceutical community.
Our strong global network of drug technology and manufacturing gives us the quality and regulatory capability to meet the demands of various niche markets.



